scholarly journals Erythema multiforme in the esophagus

2021 ◽  
Vol 84 (3) ◽  
Author(s):  
J Vandewalle ◽  
P Van Eyken ◽  
M Struyve
Keyword(s):  
Lung Cancer ◽  
Erythema Multiforme ◽  
Oral Region ◽  
Immune Mediated ◽  
Esophageal Strictures ◽  
Mucosal Involvement

Erythema multiforme is an immune-mediated mucocutaneous disorder. Mucosal involvement usually affects the oral region, the genitals or the eyes. We report a case of esophagitis caused by erythema multiforme in a patient diagnosed with lung cancer. Esophageal manifestation in erythema multiforme is rarely seen. Besides esophagitis it can lead to esophageal strictures. Erythema multiforme is mostly triggered by infection or drugs but the association with malignancy has been described.

scholarly journals Erythema multiforme in the esophagus

2021 ◽  
Vol 84 (3) ◽  
pp. 513-515
Author(s):  
J Vandewalle ◽  
P Van Eyken ◽  
M Struyve
Keyword(s):  
Lung Cancer ◽  
Erythema Multiforme ◽  
Oral Region ◽  
Immune Mediated ◽  
Esophageal Strictures ◽  
Mucosal Involvement

Erythema multiforme is an immune-mediated mucocutaneous disorder. Mucosal involvement usually affects the oral region, the genitals or the eyes. We report a case of esophagitis caused by erythema multiforme in a patient diagnosed with lung cancer. Esophageal manifestation in erythema multiforme is rarely seen. Besides esophagitis it can lead to esophageal strictures. Erythema multiforme is mostly triggered by infection or drugs but the association with malignancy has been described.

scholarly journals Acquired Factor XIII Deficiency in a Patient with Metastatic Lung Cancer

2022 ◽  
Vol 3 (1) ◽  
pp. 01-03
Author(s):  
Ana Sofia Mendes ◽  
Marco Dias ◽  
Sara Morais ◽  
Raque Romão ◽  
Bernardo Teixeira ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Neutralizing Antibodies ◽  
Factor Xiii ◽  
Process Analysis ◽  
Clinical Report ◽  
Bleeding Tendency ◽  
Metastatic Nsclc ◽  
Immune Mediated ◽  
Clinical Records ◽  
Fxiii Deficiency

Acquired factor XIII (FXIII) deficiency can result in life-long bleeding tendency and can be caused by enhanced consumption, impaired synthesis, or as an immune-mediated process. The latter can be related with solid neoplasms, through neutralizing or non-neutralizing antibodies. The relationship between FXIII activity and non-small cell lung cancer (NSCLC) is not well established. This case report is about a patient with NSCLC and acquired FXIII deficiency. Materials and Methods: Clinical records were obtained through the electronic process analysis, and the confidentiality of the patient was always assured. Results and Discussion: A 70-year-old male with no relevant past medical history and a recently diagnosed metastatic NSCLC was admitted for priapism. Five days later, a he developed a bleeding disorder, with slightly elevated coagulation times and normal fibrinogen levels and platelets count. FXIII level was found to be decreased (0.24 IU/mL) and FXIII plasma mixing studies did not confirm the presence of a neutralizing inhibitor. The FXIII level correction with standard plasma mixing studies was in favour of a non-neutralizing antibody. Despite treatment, haemorrhage control was not achieved and the patient died. Conclusion: This clinical report describes a rare case of a patient with metastatic NSCLC presenting a severe haemorrhagic event caused by FXIII deficiency immune-mediated by non-neutralizing antibodies and subsequent increased clearance.

scholarly journals Adenovirus-induced Erythema Multiforme: Eye and Genital Mucosal Involvement is Specific, Whereas Oral and Cutaneous Involvement is Not

2020 ◽  
Vol 100 (13) ◽  
pp. adv00181
Author(s):  
A Calas ◽  
C Lheure ◽  
C Bernigaud ◽  
J Meritet ◽  
P Sohier ◽  
...  
Keyword(s):  
Erythema Multiforme ◽  
Cutaneous Involvement ◽  
Mucosal Involvement

Head and Neck Manifestations of Erythema Multiforme in Children

1994 ◽  
Vol 111 (3P1) ◽  
pp. 236-242 ◽  
Author(s):  
Michael G. Stewart ◽  
Newton O. Duncan ◽  
Daniel J. Franklin ◽  
Ellen M. Friedman ◽  
Marcelle Sulek
Keyword(s):  
Oral Cavity ◽  
Toxic Epidermal Necrolysis ◽  
Head And Neck ◽  
Erythema Multiforme ◽  
Medication Use ◽  
Stevens Johnson Syndrome ◽  
Striking Increase ◽  
Johnson Syndrome ◽  
Mucosal Involvement ◽  
Mucous Membranes

Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis are related disorders of skin and mucous membranes, which are typically associated with antecedent medication use or infection. We review 108 cases of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis from Texas Children's Hospital, Houston, Texas, from 1981 to 1991, and illustrate the characteristic skin and mucosal lesions. In addition, we describe in detail two unusual cases requiring intensive airway management. Head and neck manifestations were present in 4 of 79 patients (5%) with erythema multiforme and 26 of 28 patients (93%) with Stevens-Johnson syndrome. In Stevens-Johnson syndrome, mucosal involvement of the lip (93%), conjunctiva (82%), oral cavity (79%), and nose (36%) were most common. Antecedent medication use was identified in 59% of erythema multiforme patients and 68% of Stevens-Johnson syndrome patients. We note a striking increase in the number of cases in our series caused by cephalosporins. Fifty percent of Stevens-Johnson syndrome patients required supplemental hydration or alimentation because of the severity of the oral cavity involvement. The head and neck mucosal manifestations largely respond to local care, and the routine use of prophylactic antibiotics or systemic steroids is not recommended.

Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy

Lung Cancer ◽  
2018 ◽  
Vol 120 ◽  
pp. 149-151 ◽  
Author(s):  
Chih-Chieh Yen ◽  
Hui-Chen Su ◽  
Chang-Yao Chu ◽  
Shi-Jie Lai ◽  
Jing-Jou Yan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patient ◽  
Treatment Response ◽  
Lung Cancer Patient ◽  
Axonal Polyneuropathy ◽  
Immune Mediated

Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21024-e21024
Author(s):  
Justin Chau ◽  
Meeta Yadav ◽  
Ben Liu ◽  
Muhammad Furqan ◽  
Qun Dai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Gut Microbiota ◽  
Treatment Response ◽  
Gut Microbiome ◽  
Operational Taxonomic Unit ◽  
Geographic Region ◽  
Organ Function ◽  
Immune Mediated ◽  
Α Diversity ◽  
Clinical Trial Information

e21024 Background: Though the gut microbiome has been associated with immunotherapy (ICI) efficacy in certain cancers, similar correlations between microbiomes at other body sites with treatment response and immune related adverse events (irAEs) in lung cancer (LC) patients receiving ICIs have not been made. We designed a prospective cohort study conducted from 2018-2020 at a single-center academic institution to assess for correlations between the microbiome in various body sites with treatment response and development of irAEs in LC patients treated with ICIs. Methods: Patients with histopathologically confirmed, unresectable/advanced/metastatic LC planned to undergo ICI-based therapy were enrolled between September 2018 and June 2019. Patients must have had measurable disease, ECOG 0-2, and good organ function to be included. Data was collected for analysis from January 2019 to October 2020. Nasal, buccal and gut microbiome samples were obtained prior to ICI initiation, at development of irAEs, improvement of irAEs to grade 1 or less, and at disease progression. 16S rRNA sequenced data was mapped to the SILVA 13.2 database; operational taxonomic unit clusters were analyzed using MicrobiomeAnalyst and METAGENassist. Results: 37 patients were enrolled, and 34 patients were evaluable for this report. 32 healthy controls (HC) from the same geographic region were included to compare baseline gut microbiota. Compared to HC, LC gut microbiota exhibited significantly lower α-diversity. The gut microbiome of patients who did not suffer irAEs were found to have relative enrichment of Bifidobacterium ( p = 0.001) and Desulfovibrio ( p = 0.0002). Responders to combined chemoimmunotherapy exhibited increased Clostridiales ( p = 0.018) but reduced Rikenellaceae ( p = 0.016). In responders to chemoimmunotherapy we also observed enrichment of Finegoldia in nasal microbiome, and increased Megasphaera but reduced Actinobacillus in buccal samples. Longitudinal samples exhibited a trend of α-diversity and certain microbial changes during the development and resolution of irAEs. Conclusions: This pilot study identified significant differences in the gut microbiome between HC and LC patients, and correlates specific bacterial genera to ICI response and irAEs in LC. In addition, it suggests potential predictive utility in nasal and buccal microbiomes, warranting further validation with a larger cohort and mechanistic dissection using preclinical models. Clinical trial information: NCT03688347.

scholarly journals Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

2016 ◽  
Vol 9 (3) ◽  
pp. 826-832 ◽  
Author(s):  
Tatsuo Kimura ◽  
Junko Sowa-Osako ◽  
Toshiyuki Nakai ◽  
Ayako Ohyama ◽  
Tomoya Kawaguchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Erythema Multiforme ◽  
Anaplastic Lymphoma Kinase ◽  
Fusion Gene ◽  
Skin Lesions ◽  
University Hospital ◽  
Oral Drug ◽  
Passive Smoker ◽  
Anaplastic Lymphoma ◽  
First Case

Background: Alectinib is an oral drug developed for the treatment of patients with fusion gene encoding echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-rearranged non-small cell lung cancer (NSCLC). Here, we present the case of a patient treated with alectinib who developed a hypersensitivity reaction with successful rechallenge treatment. Case Presentation: A 39-year-old woman who was a passive smoker was referred to Osaka City University Hospital for the evaluation of a skin event caused by treatment for NSCLC with the fusion gene EML4-ALK. The skin reaction was observed on the anterior chest, upper arms, and ear auricles on day 11 of treatment with oral alectinib. The skin event presented as widely distributed erythematous macules that were confluent, indicating a severe and life-threatening form. The skin lesions started to resolve after the initiation of treatment with 40 mg prednisolone. After regrowth of the tumor, she received a rechallenge program for alectinib for 2 weeks; thereafter, alectinib treatment was successfully reinitiated. Conclusion: To the best of our knowledge, we present the first case in which alectinib, which binds to the adenosine triphosphate site of EML4-ALK, induced erythema multiforme. Moreover, successful readministration of alectinib through our rechallenge program has not been reported so far.

scholarly journals Regenerative lineages and immune-mediated pruning in lung cancer metastasis

2020 ◽  
Vol 26 (2) ◽  
pp. 259-269 ◽  
Author(s):  
Ashley M. Laughney ◽  
Jing Hu ◽  
Nathaniel R. Campbell ◽  
Samuel F. Bakhoum ◽  
Manu Setty ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Metastasis ◽  
Lung Cancer Metastasis ◽  
Immune Mediated

scholarly journals Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer

2018 ◽  
Vol 88 (2) ◽  
Author(s):  
Elena Bargagli ◽  
Viola Bonti ◽  
Alessandra Bindi ◽  
Vieri Scotti ◽  
Massimo Pistolesi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Toxicity ◽  
Lung Damage ◽  
Radiation Recall ◽  
Cryptogenic Organizing Pneumonia ◽  
Immune Mediated ◽  
Radiological Pattern ◽  
High Doses ◽  
Recall Pneumonitis ◽  
Immune Suppressor

Patients treated for lung cancer may develop lung toxicity induced by chemotherapy (DILD), radiation or combined radiation recall pneumonitis. In the literature, some cases of immune-mediated pneumonitis have been reported associated with immunotherapy. The clinical and radiologic features of interstitial lung toxicity are unspecific, dyspnoea and dry cough are the most common symptoms while the most frequent radiological pattern is the cryptogenic organizing pneumonia (COP). Why only some individuals treated with these drugs develop interstitial lung toxicity is unclear.In the last few years some studies have reported the utility of KL 6 for the evaluation of DILD. The treatment is based on high doses of systemic steroids or immune suppressor. In this study we report severe interstitial lung damage in patients treated with different anti-blastic, immune and radiation therapies. Treated with surgery, chemotherapy, immuno and radiotherapy for lung cancer, they unfortunately died of severe DILD.

Sign in / Sign up

Export Citation Format

Share Document